High-Density Lipoprotein (HDL), commonly known as “good cholesterol,” is traditionally associated with cardiovascular health. However, emerging research has uncovered intriguing roles for HDL in the context of cancer. While its primary function is to transport cholesterol from the arteries back to the liver for elimination, HDL also plays complex roles in tumor development and progression, making it a subject of growing interest in oncology.

HDL’s Protective and Harmful Roles in Cancer

In some studies, HDL appears to have protective properties against cancer. It exhibits antioxidant and anti-inflammatory effects, which may hinder cancer development by limiting oxidative damage and reducing inflammation—two factors known to contribute to tumor formation. HDL also assists in maintaining the integrity of cell membranes and modulates immune responses, which may help protect against malignancy.

However, paradoxically, HDL may also facilitate cancer progression in certain contexts. Cancer cells often hijack HDL’s cholesterol-transporting properties, using it to fuel their growth. Cholesterol is a critical component in cell membranes, and fast-dividing cancer cells require ample cholesterol for membrane synthesis. Increased levels of HDL receptors, such as Scavenger Receptor Class B Type I (SR-BI), have been observed in some cancers, allowing tumor cells to access cholesterol more easily and thereby enhance their growth.

Targeting HDL in Cancer Therapy

Given HDL’s dual role, researchers are exploring ways to target HDL metabolism in cancer therapy. One potential approach is to block SR-BI receptors on cancer cells, which could prevent them from utilizing HDL cholesterol. Additionally, lowering HDL levels in certain cancer patients may reduce the availability of cholesterol for tumor growth, though more research is needed to confirm this strategy.